Novamind partners with Merck on treatment for depression
Mental health company Novamind has been selected to work alongside pharmaceutical company Merck & Co on a clinical trial focused on treatment-resistant depression (TRD). The company’s subsidiary, Cedar Clinical Research (CCR) will act as a key research site for a phase II study assessing the efficacy and safety of Merck’s new drug for TRD. TRD […]
Novamind partners with Merck on treatment for depression Read More »